LSD

🧠 Depression

🧪 Addiction

🆕 📄 Title: Efficacy and Safety of LSD in the Treatment of Mental and Substance Use Disorders: A Systematic Review of Randomized Controlled Trials
👥 Authors: Maria Helha Fernandes-Nascimento, Priscila Weber, André Brooking Negrão, Ricardo Alberto Moreno, João Paulo Lotufo, José Carlos Fernandes Galduróz
🔗 Link: Read Full Study on PubMed

🧠 Summary: This systematic review examined 11 randomized controlled trials (RCTs) evaluating LSD’s effects on mental health and substance use disorders, including trials from the 1960s–70s and a few modern studies. It aimed to synthesize evidence on LSD's efficacy and safety in therapeutic contexts.

📊 Results:

• LSD demonstrated a small but statistically significant benefit in reducing symptoms related to substance use disorders (SMD = 0.19, 95% CI [0.06–0.32], p < 0.01)

• No heterogeneity was observed across studies (I² = 0%)

• Adverse events were poorly reported in many studies, but only one serious event was documented, suggesting a generally favorable short-term safety profile

✅ Conclusion: LSD shows therapeutic promise, particularly for substance use disorders, with limited short-term safety concerns. However, the findings are limited by the age of most trials and incomplete reporting. High-quality modern research is needed to fully establish LSD’s clinical role.

📚 Citation: Fernandes-Nascimento MH, Weber P, Negrão AB, et al. Psychiatry Research. 2025 Sep;336:116001. doi: 10.1016/j.psychres.2025.116001

💥 Trauma / PTSD

🔁 OCD

😰 Anxiety

📄 Title: Phase 2b Trial of MM‑120 (Lysergide D‑Tartrate) for Treatment of Generalized Anxiety Disorder

👥 Author/Source: MindMed Inc. Phase 2b clinical trial, reported via company press release (Dec 14, 2023)

🔗 Link (Primary Source): MindMed Press Release – Topline Results d1io3yog0oux5.cloudfront.net+15ir.mindmed.co+15businesswire.com+15

🧠 Summary:

In this randomized, double-blind, placebo-controlled Phase 2b trial involving 198 adults with moderate-to-severe GAD, a single 100 µg dose of MM‑120 (oral LSD) led to:

• 🕒 Rapid onset of anxiety relief — reductions in HAM‑A scores as early as Day 2

• 📉 7.6‑point greater reduction vs placebo on HAM‑A at Week 4 (p = 0.0004; Cohen’s d = 0.88)

• ✅ 78% response (≥50% reduction) and 50% remission (HAM‑A ≤7) at Week 4

• 🔄 Durable effects through Week 12: 65% maintained response and 48% maintained remission psychiatrictimes.com+5ir.mindmed.co+5psychiatrictimes.com+5nypost.com+9ir.mindmed.co+9psychiatrictimes.com+9

• 🚧 Breakthrough Therapy designation from FDA in March 2024 en.wikipedia.org+5ir.mindmed.co+5drugtopics.com+5

• ⚠️ Well tolerated, with mild-to-moderate, transient adverse events like visual illusions, headache, nausea, and dizziness during the dosing day nypost.com+4ir.mindmed.co+4ir.mindmed.co+4

🍽️ Eating Disorders

🧍‍♂️ Personality Disorders

🔥 Chronic Pain

🧩 ADHD 

📄 Title: Safety and Efficacy of Repeated Low‑Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial

👥 Authors: Lorenz Mueller, Joyce Santos de Jesus, Yasmin Schmid, Felix Müller, Anna Becker, Aaron Klaiber, Isabelle Straumann, Dino Luethi, Eline C. H. M. Haijen, Petra P. M. Hurks, Kim P. C. Kuypers, Matthias E. Liechti (2025)

🔗 Link (Primary Source): Read Full Study on PubMed psypost.orgjamanetwork.com+5pubmed.ncbi.nlm.nih.gov+5adhdevidence.org+5

🧠 Summary:

This Phase 2A, multicenter, double‑blind, placebo‑controlled trial evaluated repeated low‑dose LSD (20 µg twice weekly for 6 weeks) versus placebo in 53 adults with moderate-to-severe ADHD conducted at centers in Basel and Maastricht.

• Both groups saw clinically significant reductions in ADHD symptoms (measured by AISRS).

• LSD group improved by −7.1 points, while the placebo group improved by −8.9 points, with no statistically significant difference between them jamanetwork.com+10pubmed.ncbi.nlm.nih.gov+10researchgate.net+10.

• LSD was physically safe and well tolerated, with no serious adverse events reported en.wikipedia.org+12pubmed.ncbi.nlm.nih.gov+12adhdevidence.org+12.

Conclusion:  Repeated low-dose LSD was safe in an outpatient setting but did not outperform placebo in reducing ADHD symptoms. This study underscores both the importance of rigorously controlled trials in microdosing research and the need to investigate different dosing regimens or populations.

📚 Evidence & Citation Policy

All research summaries on this site are based on peer-reviewed studies, clinical trials, meta-analyses, and systematic reviews. Each study includes citation details with direct hyperlinks to PubMed or the publishing journal. While we strive for accuracy, readers are encouraged to review the source materials directly. This site does not offer medical advice; for treatment decisions, please consult a licensed clinician.